Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Do antiretrovirals reduce the risk of non-AIDS-defining malignancies?

Do antiretrovirals reduce the risk of non-AIDS-defining malignancies? Do antiretrovirals reduce the risk of non-AIDS-defining malignancies? a b Michael J. Silverberg and Donald I. Abrams Division of Research, Kaiser Permanente Northern Purpose of review California, Oakland and Hematology-Oncology There is an increasing burden of non-AIDS-defining malignancies (NADMs) in the Division, San Francisco General Hospital, University of California San Francisco, San Francisco, California, antiretroviral therapy (ART) era. The recent literature is reviewed with respect to NADM USA risk, ART use, and immune function. Correspondence to Michael J. Silverberg, PhD, MPH, Recent findings Division of Research, Kaiser Permanente Northern Recent studies have increasingly focused on individual ART use, CD4 T-cell counts, and California, 2000 Broadway, Oakland, CA 94612, USA Tel: +1 510 891 3801; fax: +1 510 891 3761; the risk of NADMs. Certain NADMs have been shown to have a reduced risk with ART e-mail: Michael.J.Silverberg@kp.org use including liver, breast, colorectal, and lung cancers. NADMs associated with Current Opinion in HIV and AIDS 2009, 4:42–51 immunosuppression included Hodgkin’s lymphoma, oral/pharynx, lung, anal, and colorectal cancers. Despite the potential protective effect of ART on some NADMs, recent studies evaluating calendar era trends have noted an increased risk of Hodgkin’s lymphoma and anal cancer and no change in risk for http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Do antiretrovirals reduce the risk of non-AIDS-defining malignancies?

Abrams, Donald I
Current Opinion in HIV and Aids , Volume 4 (1) – Jan 1, 2009
Download PDF
10 pages

Loading next page...
 
/lp/wolters-kluwer-health/do-antiretrovirals-reduce-the-risk-of-non-aids-defining-malignancies-Z0JnZkPHuj

References (87)

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e32831a9875
pmid
19339938
Publisher site
See Article on Publisher Site

Abstract

Do antiretrovirals reduce the risk of non-AIDS-defining malignancies? a b Michael J. Silverberg and Donald I. Abrams Division of Research, Kaiser Permanente Northern Purpose of review California, Oakland and Hematology-Oncology There is an increasing burden of non-AIDS-defining malignancies (NADMs) in the Division, San Francisco General Hospital, University of California San Francisco, San Francisco, California, antiretroviral therapy (ART) era. The recent literature is reviewed with respect to NADM USA risk, ART use, and immune function. Correspondence to Michael J. Silverberg, PhD, MPH, Recent findings Division of Research, Kaiser Permanente Northern Recent studies have increasingly focused on individual ART use, CD4 T-cell counts, and California, 2000 Broadway, Oakland, CA 94612, USA Tel: +1 510 891 3801; fax: +1 510 891 3761; the risk of NADMs. Certain NADMs have been shown to have a reduced risk with ART e-mail: Michael.J.Silverberg@kp.org use including liver, breast, colorectal, and lung cancers. NADMs associated with Current Opinion in HIV and AIDS 2009, 4:42–51 immunosuppression included Hodgkin’s lymphoma, oral/pharynx, lung, anal, and colorectal cancers. Despite the potential protective effect of ART on some NADMs, recent studies evaluating calendar era trends have noted an increased risk of Hodgkin’s lymphoma and anal cancer and no change in risk for

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Jan 1, 2009

There are no references for this article.